哮喘联盟

   摘要
   简介：哮喘相关的死亡，80%发生于病情未得到控制的患者；哮喘相关的花费，50%用于病情未得到控制的患者。尽管哮喘治疗需要的花费很大，但其导致的直接费用和生产力的损失直到最近才被广泛研究，部分是由于新的且更贵的治疗方法的引进。一项在意大利艾米利亚-罗马涅省地区医疗服务机构中进行的为期5年的以人群为基础的预算影响模型分析研究，比较了联合支气管热成型术(BT)辅助治疗与标准治疗联合或不联合奥玛珠单抗(OMAL)辅助治疗重症、未控制的哮喘患者对预算的影响。
   方法：该模型对比了2种方案的预算影响：第一种方案研究了单用SC治疗或SC联合OMAL的人群；第2中方案研究了单用SC治疗、或SC联合OMAL或BT的人群。
   结果：艾米利亚-罗马涅省的哮喘患者，BT治疗第一年所需的费用是17.7百万欧元；第三、四、五年的花费可依次减少1百万欧元，10.5百万欧元和19.2百万欧元。
   结论：尽管BT或OMAL的补充治疗增加了直接花费，但是不仅可以帮助临床医生满足更多患者的需求，而且降低了急诊次数和住院次数，并且从长远来看，可以节省花费。
 

（林江涛 审校）
Adv Ther. 2014 Jul 10. [Epub ahead of print]

 

A Budget Impact Analysis of Bronchial Thermoplasty for Severe Asthma in Clinical Practice.
 

Menzella F1, Zucchi L, Piro R, Galeone C, Castagnetti C, Facciolongo N.
 

ABSTRACT
INTRODUCTION: Fully 80% of asthma-related deaths occur in patients with uncontrolled disease and 50% of all costs are attributable to this subgroup. Although asthma is costly, direct costs and loss of productivity have only recently been extensively studied, partly as a result of the introduction of new and more costly treatment options. A 5-year population-based budget impact model in the perspective of the Emilia Romagna of Italy regional healthcare service compared the impact of adding adjuvant bronchial thermoplasty (BT) for a population of patients with severe, uncontrolled asthma treated with standard care (SC) with or without adjuvant omalizumab (OMAL).
METHODS: The model compared the budget impact of two scenarios: the first examined a population treated either with SC alone or with administration of OMAL concurrent to SC; the second examined a population treated either with SC alone or with either the concurrent administration of OMAL or BT.
RESULTS: The cost for treating asthmatics patients in Emilia Romagna with BT would require 17.7 million Euros during the initial year; these costs would be offset by savings of 1 million Euros, 10.5 million Euros, and up to 19.2 million Euros during third, fourth, and fifth years, respectively.
CONCLUSION: Despite the increase in direct costs, the complementary treatment of patients with either BT or OMAL in addition to SC may not only help the clinician to meet the needs of a greater number of patients, but also decreases emergency room visits and hospitalizations, as well as generates economic savings in the longer term.
 

Adv Ther. 2014 Jul 10. [Epub ahead of print]